What is the current valuation of the US Radioligand Therapy Rlt Market?

The US Radioligand Therapy Rlt Market was valued at 1.71 USD Billion in 2024. Read More

What is the projected market size for the US Radioligand Therapy Rlt Market by 2035?

The market is projected to reach 4.2 USD Billion by 2035. Read More

What is the expected CAGR for the US Radioligand Therapy Rlt Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 8.52%. Read More

Which applications dominate the US Radioligand Therapy Rlt Market?

Oncology is the leading application, with a valuation projected to grow from 0.85 to 1.95 USD Billion. Read More

What are the key end-use segments in the US Radioligand Therapy Rlt Market?

Hospitals are the primary end-use segment, expected to increase from 0.85 to 1.95 USD Billion. Read More

What types of radioligands are prevalent in the US market?

Alpha emitters and beta emitters are significant, with projected valuations of 0.5 to 1.2 USD Billion and 0.8 to 2.0 USD Billion, respectively. Read More

How is the administration route segmented in the US Radioligand Therapy Rlt Market?

The intravenous route is anticipated to grow from 0.85 to 1.95 USD Billion, leading the administration segment. Read More

Which diseases are primarily targeted by radioligand therapies in the US?

Prostate cancer is the leading target disease, with a projected market size increasing from 0.85 to 1.95 USD Billion. Read More

Who are the key players in the US Radioligand Therapy Rlt Market?

Key players include Novartis, Bayer, AstraZeneca, and Bristol-Myers Squibb, among others. Read More

What trends are influencing the growth of the US Radioligand Therapy Rlt Market?

The increasing prevalence of cancer and advancements in radioligand technology are likely driving market growth. Read More

US Radioligand Therapy Market

ID: MRFR/Pharma/63969-HCR

200 Pages

Rahul Gotadki

Last Updated: March 28, 2026

US Radioligand Therapy RLT Market Research Report By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End User (Hospitals & Clinics, Diagnostic Centers, Others) - Growth & Industry Forecast 2025 To 2035

US Radioligand Therapy Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Neurology
  4. 4.1.4 Endocrinology
2. 4.2 Healthcare, BY End Use (USD Billion)
  1. 4.2.1 Hospitals
  2. 4.2.2 Diagnostic Centers
  3. 4.2.3 Research Institutions
  4. 4.2.4 Pharmaceutical Companies
3. 4.3 Healthcare, BY Type of Radioligand (USD Billion)
  1. 4.3.1 Alpha Emitters
  2. 4.3.2 Beta Emitters
  3. 4.3.3 Auger Electron Emitters
  4. 4.3.4 Radionuclide Generators
4. 4.4 Healthcare, BY Administration Route (USD Billion)
  1. 4.4.1 Intravenous
  2. 4.4.2 Oral
  3. 4.4.3 Intratumoral
5. 4.5 Healthcare, BY Target Disease (USD Billion)
  1. 4.5.1 Prostate Cancer
  2. 4.5.2 Neuroendocrine Tumors
  3. 4.5.3 Lymphoma
  4. 4.5.4 Thyroid Cancer
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ipsen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Lantheus Medical Imaging (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY END USE
4. 6.4 US MARKET ANALYSIS BY TYPE OF RADIOLIGAND
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 US MARKET ANALYSIS BY TARGET DISEASE
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
  3. 7.2.3 BY TYPE OF RADIOLIGAND, 2026-2035 (USD Billion)
  4. 7.2.4 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
  5. 7.2.5 BY TARGET DISEASE, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Endocrinology

Healthcare By End Use (USD Billion, 2026-2035)

Hospitals
Diagnostic Centers
Research Institutions
Pharmaceutical Companies

Healthcare By Type of Radioligand (USD Billion, 2026-2035)

Alpha Emitters
Beta Emitters
Auger Electron Emitters
Radionuclide Generators

Healthcare By Administration Route (USD Billion, 2026-2035)

Intravenous
Oral
Intratumoral

Healthcare By Target Disease (USD Billion, 2026-2035)

Prostate Cancer
Neuroendocrine Tumors
Lymphoma
Thyroid Cancer

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”